die('
Site is under construction
Dear site users
Site is under construction.
The site will be ready in less than 24 hours.
We are sorry for the inconvenience.
www.yektaweb.com
');
Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61882/rbmb
en
jalali
1401
11
1
gregorian
2023
2
1
11
4
online
1
fulltext
en
Molecular and Immunohistochemical Alterations in Breast Cancer Patients in Upper Egypt
زیست شناسی ملکولی
Molecular Biology
مقالات اصلی
Original Article
<div style="text-align: justify;"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt">Background:</span></span></span></i></b><b><i> </i></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt">Breast cancer (BC) plays a major public health in Egyptian woman. In Upper Egypt, there is an increase in incidence of BC compared to other Egyptian areas. Triple-negative BC, estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-neu-negative, is a high-risk BC that lacks the benefit of specific therapy that targets these proteins. Accurate determination of Caveolin-1(Cav-1), Caveolin-2 (Cav-2) and HER-2/neu status have become of major clinical significance in BC by focusing about its role as a tumor marker for response to different therapies.</span></span></span><br>
<span lang="IN" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt"></span></span></span><span lang="IN" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt"></span></span></span><span lang="IN" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt"></span></span></span></span></span></span></span><br>
<span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt">Methods:</span></span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">The present study was performed on 73 female BC patients in the South Egypt Cancer Institute. Blood samples were used for Cav-1, Cav-2, and HER-2/neu genes amplification and expression. In addition, immunohistological analysis of mammaglobin, GATA3, ER, PR, and HER-2/neu was done.</span></span><br>
<span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt"></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="text-autospace:none"><span style="font-family:Calibri,sans-serif"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt">Results:</span></span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">There was a statistically significant association between Cav-1, 2 and HER-2/neu genes expression and the age of patients (P< 0.001). There are increase in the level of Cav-1, 2 and increase in HER-2/neu mRNA expression in groups treated with chemotherapy and group treated with both chemotherapy and radiotherapy compared to each group baseline level of genes mRNA expression before treatment. On the contrary, the group treated with chemotherapy, radiotherapy and hormonal therapy revealed increase on the level of Cav-1, 2 and HER-2/neu mRNA expression when compared with their baseline for the same patients before treatment.</span></span></span></span></span></span></span><br>
<br>
<span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="text-autospace:none"><span style="font-family:Calibri,sans-serif"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt">Conclusions:</span></span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="letter-spacing:-.3pt">Noninvasive molecular biomarkers such as Cav-1 and Cav-2 have been proposed for use in the diagnosis and prognosis for women with BC.</span></span></span></span></span></span></span></span></div>
Breast Cancer, Caveolin-1, ER, GATA-3, HER-2/neu, Mammaglobin, PR, 2.
532
546
http://rbmb.net/browse.php?a_code=A-10-1149-1&slc_lang=en&sid=1
Sanaa
Hagag
100319475328460016768
100319475328460016768
No
Radiation Biology department, National Center for Radiation Research & Technology, Egyptian Atomic Energy Authority, Nasr City, 8029, Cairo, Egypt.
Ahmad
Kodous
ahmad.kodous@eaea.org.eg
100319475328460016769
100319475328460016769
Yes
Radiation Biology department, National Center for Radiation Research & Technology, Egyptian Atomic Energy Authority, Nasr City, 8029, Cairo, Egypt.
Hebat Allah
Shaaban
100319475328460016770
100319475328460016770
No
Pathology department, National Cancer Institute, Cairo University, Giza, Egypt.